This inventor holds 1 USPTO granted patent. Top assignee: Bayer Aktiengesellschaft. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Jens Ergüden: Innovator in CNS Disease Treatment
Introduction
Jens Ergüden is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of neuroscience through his innovative research and patenting efforts. His work focuses on developing treatments for central nervous system (CNS) disorders, which are critical for improving mental health.
Latest Patents
Ergüden holds a patent for "2-aminocarbonyl-5(2H)-isoxazolones as ligands of a DFP-binding site treatment of CNS-diseases." This invention relates to novel 2-aminocarbonyl-5(2H)-isoxazolones that act as selective ligands for a high-affinity binding site of diisopropyl fluorophosphate (DFP) on brain membranes. The patent aims to provide prophylaxis and treatment for various CNS disorders, including cognitive disorders, depression, schizophrenia, and anxiety. He has 1 patent to his name.
Career Highlights
Jens Ergüden is associated with Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. His role at Bayer allows him to collaborate with other experts in the field and contribute to groundbreaking research aimed at improving mental health treatments.
Collaborations
Throughout his career, Ergüden has worked alongside esteemed colleagues such as Franz-Josef Van Der Staay and Joachim Schuhmacher. These collaborations have further enhanced his research and development efforts in the treatment of CNS diseases.
Conclusion
Jens Ergüden's innovative work in the field of CNS disease treatment exemplifies the importance of research and patenting in advancing medical science. His contributions are vital for the development of effective therapies for mental health disorders.